Are USPSTF lung cancer screening recommendations reaching patients?

The U.S. Preventive Services Task Force (USPSTF) recommendation for lung cancer screening finalized last year has been slow to gain the awareness and notoriety of other cancer screening recommendations, according to a panel discussion on non-small cell lung cancer conducted by The American Journal of Manage Care (AJMC).

Last year, the USPSTF recommended annual lung cancer screenings with low-dose CT for adults aged 55-80 years who have smoked 30 pack years. The draft recommendation, released July 29, 2013, and the finalized recommendation issued on Dec. 31, 2013, both received a high level of press attention.

Despite the press, screenings for lung cancer did not see a surge similar to that of other highly-publicized screening efforts for breast and colon cancers, said Corey J. Langer, MD, professor of medicine, Abrahamson Cancer Center, University of Pennsylvania, Philadelphia, during the panel discussion.

“It’s amazing how few patients or family members are aware of this,” Langer said. “The impact and the general notice of the [National Lung Screening Trial] has not penetrated.”

The panel discussion also included David J. Sugarbaker, MD, chief of thoracic surgery at Brigham and Women’s Hospital in Boston, and Steven Peskin, MD, senior medical director, Horizon Healthcare Innovations, Horizon Blue Cross Blue Shield New Jersey. The discussion was led by Michael Chernew, PhD, a health economist at Harvard University and co-editor-in-chief of AJMC.

The full discussion can be heard here.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.